Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

Cancer

Volumn 104, Issue 8, 2005, Pages 1656-1660

  Tefferi, Ayalew ^a   Dingli, David ^a   Li, Chin Yang ^a   Dewald, Gordon W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytogenetic abnormalities; Leukemic transformation; Myelofibrosis; Myeloid metaplasia; Prognosis; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 20; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME DELETION 13; COHORT ANALYSIS; CYTOGENETICS; FEMALE; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MYELOFIBROSIS; MYELOID FIBROSIS WITH MYELOID METAPLASIA; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COHORT STUDIES; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 26444470779     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21358     Document Type: Article

References (24)

1. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-108.
2. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
3. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68:205-212.
4. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
5. Barosi G, Berzuini C, Liberate LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia [see comments]. Br J Haematol. 1988;70:397-401.
6. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990;75:4-9.
7. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102.
8. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
9. Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72:855-859.
10. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
11. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
13. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001;25:829-838.
14. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106:682-688.
15. Siena S, Bregni M, Brando B, et al. Flow cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: comparative analysis of different CD34 monoclonal antibodies. Haematologica. 1991;76:330-333.
16. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet. 1985;18:1-10.
17. Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol. 1998;11:819-848.
18. Pastore C, Nomdedeu J, Volpe G, et al. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer. 1995;14:106-111.
19. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-426.
20. Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981-986.
21. Bench AJ, Nacheva EP, Hood TL, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene. 2000;19:3902-3913.
22. Wattel E, Lai JL, Hebbar M, et al. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res. 1993;17:921-926.
23. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
24. Tefferi A, Deeg HJ. Deciding on transplantation for myelofibrosis: setting the record straight. Mayo Clin Proc. 2004;79:953-954.